Search clinical trials for: DAS181

Total 41 results

Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
Ansun Biopharma, Inc.

Completed

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

DAS181 in Patients With Parainfluenza

Parainfluenza Infection
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

DAS181 Single Dose Escalation Study in Healthy Adults

Healthy

United States
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Single Dose Escalating Study of DAS181 in Adults

Influenza

United States
Renmin Hospital of Wuhan University
Ansun Biopharma, Inc.

Completed

DAS181 for Severe COVID-19: Compassionate Use

COVID-19

China
Ansun Biopharma, Inc.

Withdrawn

DAS181 for STOP COVID-19

COVID-19

Italy
Ansun Biopharma, Inc.

Unknown

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) (STOP-Flu)

Influenza Infection | SAD-RV Infection and COVID-19

China
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Antiviral DAS-181-F04 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Antiviral DAS181-F03

Influenza

United States
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis (DAS181)

Bronchiectasis | Asthma

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

Chronic Hepatitis c

China
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Influenza

United States
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Day One Biopharmaceuticals, Inc.

Available

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Low-grade Glioma
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

Healthy Chinese Volunteers

China
Sunshine Lake Pharma Co., Ltd.

Completed

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

Renal Impairment

China
Karen D. Wright, MD
National Cancer Institute (NCI); Pacific Pediatric Neuro-Oncology Consortium; Day One Biopharmaceuticals, Inc... and other collaborators

Active, not recruiting

DAY101 In Gliomas and Other Tumors

Low-grade Glioma

United States
Day One Biopharmaceuticals, Inc.
Pacific Pediatric Neuro-Oncology Consortium

Recruiting

A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)

Advanced Solid Tumor | Low-grade Glioma

United States, Israel, Korea, Republic of, Denmark, Singapore, Netherlands, Canada, Australia, Germany, Switzerland, United Kingdom
Sunshine Lake Pharma Co., Ltd.

Completed

Phase 2 Study of Yimitasvir Phosphate Capsules

Chronic HCV Infection

China
University Health Network, Toronto
Centre for Addiction and Mental Health

Recruiting

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin (PSI-1V2)

Depression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant Depression

Canada
Sunshine Lake Pharma Co., Ltd.

Completed

Phase 3 Study of Yimitasvir Phosphate Capsules

Chronic HCV Infection

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Completed

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Lawson Health Research Institute
Abbott

Completed

Optimization of Treatment With Adalimumab (Humira)

Rheumatoid Arthritis (RA)

Canada
Children's Oncology Group

Not yet recruiting

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
Day One Biopharmaceuticals, Inc.
SIOPe Brain Tumor Group LOGGIC Consortium

Recruiting

DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Low-grade Glioma

United States, Korea, Republic of, France, Germany, Spain, United Kingdom, Belgium, Denmark, Canada, Italy, Finland, Australia, Ireland, Switzerland, Netherlands, Czechia, Greece, New Zealand, Slovenia, Sweden, Hungary, Singapore, A... and more
Sabine Mueller, MD, PhD
Bristol-Myers Squibb; Day One Biopharmaceuticals, Inc.

Recruiting

Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults (PNOC029)

Craniopharyngioma | Craniopharyngioma, Child | Recurrent Craniopharyngioma

United States
Qassim University

Unknown

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

COVID-19
BioMAS Ltd

Terminated

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Chemotherapy Induced Thrombocytopenia

Israel
BioMAS Ltd

Unknown

Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts

External Genital Warts

Israel
BioMAS Ltd

Withdrawn

Topical Application of AS101 for the Treatment of Psoriasis

Mild to Moderate Psoriasis

Israel
BioMAS Ltd

Terminated

Topical Application of AS101 for the Treatment of Atopic Dermatitis

Atopic Dermatitis

Israel
BioMAS Ltd

Completed

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

Condyloma Acuminata | Wart; External Genital Organs

Israel
Rabin Medical Center

Unknown

Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Alopecia

Israel
National Cancer Institute (NCI)

Recruiting

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis

United States, Canada
BioMAS Ltd

Suspended

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
Feramda

Completed

Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

Israel
The Alfred

Unknown

A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (CISTIC)

Cystic Fibrosis

Australia
Assiut University

Completed

Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial

Rheumatoid Arthritis

Egypt

Search clinical trials for: DAS181

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations